Triagexone Injection 500 milligrams, 1 gram (Ceftriaxone Sodium Hydrate)

Adult administration

Adults and children over 12 years old should receive 1-2 g (activity) of ceftriaxone once a day by intravenous or intramuscular injection. For infections caused by severe pathogens or pathogens showing moderate sensitivity, the dosage can be increased to 4 g (activity) once a day. No change in dosages is necessary for the elderly.

Child administration

Neonates (within 14 days of birth) should receive 20-50 mg (activity) per kg of body weight once a day, not exceeding 50 mg (activity) per kg of body weight. Infants and children (from 15 days to 12 years) should receive the dosage based on their weight.

This drug should not be mixed with calcium-containing solutions or other drugs. In particular, in newborns, mixing calcium with this drug can produce precipitates leading to serious side effects, so it should never be administered. Patients who have allergies to this drug or have had hypersensitivity to cephalosporin or penicillin antibiotics should avoid using it. Additionally, in premature infants or newborns with bilirubin binding problems, this drug may be hazardous and should not be administered. Patients with severe kidney disease, those with a history of allergies, the elderly, and those in poor health should use this drug cautiously, and dosage adjustments may be required. This drug can cause various side effects such as eosinophilia, leukopenia, diarrhea, rash, liver function abnormalities, and others, so patient status must be closely monitored during administration. If severe allergic reactions or shock symptoms occur, administration should be stopped immediately and emergency treatment sought. This drug may put stress on the kidneys when used with other cephalosporin antibiotics, certain diuretics, or aminoglycoside antibiotics, so caution is advised. Women who are pregnant or breastfeeding should carefully consider the administration of this drug as it may affect the fetus or newborn. It is generally considered unsafe to administer this drug to newborns and premature infants due to the risk of bilirubin encephalopathy. The elderly may be more susceptible to side effects due to decreased physical function, so dosage and administration intervals should be adjusted and monitored. Additionally, this drug may affect blood tests or urine test results, so keep this in mind when testing. Pain at the injection site or phlebitis may occur, so it is recommended to manage the injection method and speed carefully. It is best to use this drug as soon as possible after preparation, and the prepared solution should be used within a certain period. There may be side effects such as dizziness when driving or operating machinery, so caution is needed.

Serious side effects

Hives, severe swelling (edema), chest tightness, difficulty breathing, cold sweats, paleness, severe rash with high fever, blisters, peeling skin, pain in mucous membranes of the mouth/eyes, shortness of breath or difficulty breathing, asthma attack, abnormal breathing with cough + fever, yellowing of skin or eyes (jaundice), extreme lethargy, sudden and severe headache, thunderclap headache, seizures, altered consciousness, visual disturbances, paralysis, difficulty urinating.

Mild side effects

• Eosinophilia
• leukopenia
• thrombocytopenia
• diarrhea
• rash
• increased liver enzymes
• dizziness
• headache
• bronchospasm
• loose stools

This drug should be stored in a sealed container to prevent air and moisture from entering, and it is best to store it at room temperature between 1 to 30 degrees Celsius. Proper storage will maintain the drug's effectiveness and prevent deterioration.

Appearance

Type I (Vial): A colorless and transparent vial filled with white or pale yellow powder. Type II (Mapset kit): Contains a diluent with saline injection and a transfer device.

Package unit

0.5g - 10 vials/box [1 vial x 10], 1g: Type I - 10 vials/box [1 vial x 10], 1g: Type II - 10 kits/box [1 kit x 10]